Saturday, July 11, 2026

Drug profile · INN

terconazole

terconazole (TERCONAZOLE) is a cytochrome p450 51 inhibitor. Route of administration: vaginal. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — terconazole
US status
approved
Class
Route
VAGINAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

terconazole (TERCONAZOLE) is a cytochrome p450 51 inhibitor. Route of administration: vaginal. Current US regulatory status: approved.

Key facts

INN terconazole
Brand TERCONAZOLE
Mechanism Cytochrome P450 51 inhibitor
Target Lanosterol 14-alpha demethylase
Route VAGINAL
Formulation SUPPOSITORY

Mechanism of action

Cytochrome P450 51 inhibitor

Primary target: Lanosterol 14-alpha demethylase

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. clotrimazole Cytochrome P450 51 inhibitor
  2. efinaconazole Lanosterol 14-alpha demethylase inhibitor
  3. fluconazole Cytochrome P450 51 inhibitor
  4. itraconazole Cytochrome P450 51 inhibitor
  5. ketoconazole Antiinfectives for systemic use (J02)
  6. miconazole nitrate Cytochrome P450 51 inhibitor

Frequently asked questions

What is terconazole?

terconazole (TERCONAZOLE) is a cytochrome p450 51 inhibitor. Route of administration: vaginal. Current US regulatory status: approved.

What is the brand name for terconazole?

TERCONAZOLE is a marketed brand name for terconazole. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of terconazole?

terconazole has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.